Stay updated on CM-24 Combo Study With Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the CM-24 Combo Study With Pembrolizumab Clinical Trial page.

Latest updates to the CM-24 Combo Study With Pembrolizumab Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedGastric cancer was added to the list of studied conditions and a Genetics/Rare Diseases Information Center resource was included. The page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check18 days agoChange DetectedRevision: v3.4.1 was added and v3.4.0 was removed. This change does not affect study data, eligibility, or functionality; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check32 days agoChange DetectedThe page now includes a glossary toggle (Show glossary) and displays a new 'Last Update Submitted that Met QC Criteria' indicator, along with a site revision note 'Revision: v3.4.0'. The previous elements 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.2%

- Check39 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedAdded a consolidated Locations section with California and Connecticut; removed the separate California Locations and Connecticut Locations sections and the HHS Vulnerability Disclosure footer, and updated the revision to v3.3.3.SummaryDifference0.3%

- Check89 days agoChange DetectedRevision: v3.3.2 is now displayed, replacing v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to CM-24 Combo Study With Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CM-24 Combo Study With Pembrolizumab Clinical Trial page.